RETA - Reata Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM 即時價格。貨幣為 USD。
-2.50 (-2.71%)
市場開市。 截至 11:36AM EDT。
買盤89.52 x 1200
賣出價89.74 x 800
今日波幅89.03 - 92.51
52 週波幅18.47 - 106.69
Beta 值 (5 年,每月)1.53
市盈率 (最近 12 個月)
每股盈利 (最近 12 個月)-9.34
業績公佈日2023年8月07日 - 2023年8月11日
遠期股息及收益率無 (無)
1 年預測目標價112.70
  • InvestorPlace

    The 3 Best Growth Stocks to Buy in the Biotech Sector

    Investors may want to keep an eye on biotech growth stocks, which are typically associated with the risk-on trade. Case in point: The sector ran up in January, but when the broader-market rally fizzled, it sold off hard as investors sought safer havens. Yet, with renewed optimism in the market as banking sector fears ease, the SPDR S&P Biotech ETF (NYSEARCA:XBI) is up 4.4% over the past week. Looking at the flip side of the coin, one could argue that biotech growth stocks are also a recession-pr

  • Benzinga

    Why Reata Pharma Shares Are Skyrocketing Today

    The FDA approved Reata Pharmaceuticals Inc's (NASDAQ: RETA) Skyclarys (omaveloxolone) for Friedreich's ataxia in adults and adolescents aged 16 and older. With this approval, the FDA granted a rare pediatric disease priority review voucher. The company says Skyclarys is the first therapy specifically indicated for Friedreich's ataxia. Related: Why Reata Pharmaceuticals Shares Are Falling Monday? Friedreich's ataxia is an ultra-rare, inherited neurodegenerative disorder typically diagnosed during

  • Benzinga

    Why Reata Pharmaceuticals Shares Are Falling Monday?

    According to various reports, the FDA's neuroscience expert Billy Dunn is leaving the agency after more than 15 years, effective immediately. Dunn presided over the controversial approval of Biogen Inc's (NASDAQ: BIIB) Alzheimer's disease treatment, Aduhelm (aducanumab). Dunn, 53, is retiring from the agency to "explore other opportunities," according to an internal FDA email. Dunn notified agency officials Friday, according to a person with knowledge of the situation. Reata Pharmaceuticals Inc

  • Insider Monkey

    Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Q3 2022 Earnings Call Transcript

    Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Q3 2022 Earnings Call Transcript November 8, 2022 Reata Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-2.16, expectations were $-2.18. Operator: Thank you for standing by, and welcome to the Reata Pharmaceuticals Third Quarter 2022 Financial Results and Update on Development Programs Conference Call. An audio recording of today’s webcast […]

  • Insider Monkey

    15 Most Shorted Stocks Hedge Funds Are Buying

    In this article, we will discuss the 15 most shorted stocks hedge funds are buying. You can skip our detailed overview and go directly to the 5 Most Shorted Stocks Hedge Funds Are Buying. The year 2022 has been a dynamic year for financial markets worldwide. The equity markets have come under selling pressure across […]

  • Benzinga

    FDA Pushes Decision Date For Reata's Genetic Neuromuscular Disease Candidate

    The FDA has extended the review timeline for Reata Pharmaceuticals Inc's (NASDAQ: RETA) marketing application seeking approval for omaveloxolone for Friedreich's ataxia by three months. The company recently submitted an updated Delayed-Start Analysis of the MOXIe Extension study using a March 2022 data cut-off, a new Propensity-Matched Analysis of MOXIe Extension data, and an analysis of the relevance of Nrf2, the target of omaveloxolone, to the pathophysiology of Friedreich's ataxia. Related: W

  • Benzinga

    Why Reata Pharma Shares Are Trading Lower After Q2 Earnings Update?

    Reata Pharmaceuticals Inc (NASDAQ: RETA) completed a mid-cycle communication meeting with the FDA regarding the marketing application review status for omaveloxolone for Friedreich's ataxia. The FDA stated that it had not identified any new significant issues, but it continues to have concerns regarding the strength of the efficacy evidence. The agency did not identify any significant clinical safety issues. The FDA stated that the safety review is ongoing, and they are continuing to evaluate th